BIOHENG
BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents plus extensive industry experience, and has built a complete, closed an... d automated production system in compliance with regulatory guidelines. In 2018, Bioheng has successfully raised tens of millions of RMB seeding fund from Simcere Pharmaceutical Group, aiming to accelerate the development of immunotherapy via integrating resources from both parties. Bioheng is dedicated to develop safer, effective and less expensive cell therapy drugs to benefit more patients.
BIOHENG
Industry:
Biopharma Biotechnology Clinical Trials Health Care Innovation Management
Founded:
2017-01-01
Address:
Nanjing, Jiangsu, China
Country:
China
Website Url:
http://www.bioheng.com
Total Employee:
1+
Status:
Active
Contact:
400-828-8076
Email Addresses:
[email protected]
Total Funding:
620 M CNY
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Mobile Non Scaleable Content Apple Mobile Web App Capable JQuery CDN Apple Mobile Web App Status Bar Style Cart Functionality HiChina DNS
Similar Organizations
Hangzhou Just Biotherapeutics (Just China)
Hangzhou Just Biotherapeutics is a comprehensive high-tech design company.
IFTech
IFTech Inventing Future Technology Inc. is a high tech innovation company.
Qihan Biotech
Qihan Biotech is a gene-editing organ transplantation technology developer.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
YS Biopharma
YS Biopharma is a global, fully integrated bio-pharmaceutical company.
Current Employees Featured
Founder
Investors List
Hillhouse Capital Group
Hillhouse Capital Group investment in Series B - Bioheng
Octagon Capital Partners
Octagon Capital Partners investment in Series B - Bioheng
Decheng Capital
Decheng Capital investment in Series B - Bioheng
GL Ventures
GL Ventures investment in Series B - Bioheng
BlueRun Ventures
BlueRun Ventures investment in Series B - Bioheng
Min Cui
Min Cui investment in Series B - Bioheng
Shenzhen Capital Group
Shenzhen Capital Group investment in Series B - Bioheng
Decheng Capital
Decheng Capital investment in Series A - Bioheng
Official Site Inspections
http://www.bioheng.com
- Host name: 123.59.154.172
- IP address: 123.59.154.172
- Location: Beijing China
- Latitude: 39.9288
- Longitude: 116.3889
- Timezone: Asia/Shanghai
More informations about "Bioheng"
Bioheng Therapeutics-CAR-T,UCAR-T
Bioheng Therapeutics is a clinical-stage company focused on allogeneic " off-the-shelf " universal CAR-T therapies. Founded in 2017, we aim to develop the worldโs leading allogeneic cell โฆSee details»
Bioheng - Crunchbase Company Profile & Funding
BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and โฆSee details»
Nanjing Bioheng Biotech Co., Ltd. - Drug pipelines, Patents, โฆ
Explore Nanjing Bioheng Biotech Co., Ltd. with its drug pipeline, therapeutic area, technology platform, 17 clinical trials, 9 news, and 7 literature, Disease Domain:Neoplasms, Hemic and โฆSee details»
Bioheng Therapeutics - LinkedIn
Bioheng Therapeutics is a clinical stage company focused on allogeneic / off-the-shelf CAR-T. Founded in 2017, we aim to develop the world's leading allogeneic cell therapy products to โฆSee details»
Bioheng Therapeutics Company Profile 2024: Valuation, Funding ...
Bioheng Therapeutics has raised $94.8M. Who are Bioheng Therapeuticsโs investors? Hillhouse Investment Group , Lanchi Ventures , Octagon Capital Advisors , Shenzhen Capital Group , โฆSee details»
Bioheng Company Profile: Overview and Full News Analysis
Bioheng is a biopharmaceutical company located in Jiangsu, China, specializing in the development and commercialization of innovative disease treatment products. Established in โฆSee details»
Bioheng - Products, Competitors, Financials, Employees, โฆ
Bioheng is a biopharmaceutical company focusing on the development and commercialization of disease treatment products. Use the CB Insights Platform to explore Bioheng's full profile. ...See details»
Bioheng Biotech - VentureRadar
" Bioheng is a clinical-stage biotech company focusing on the development and commercialization of novel allogeneic cellular immunotherapy for immediate treatment to cancer patients, which โฆSee details»
Contact-Bioheng Therapeutics
Bioheng Therapeutics Contact Bioheng Therapeutics is a clinical stage company focused on allogeneic / off-the-shelf CAR-T. About. About Bioheng. History. Science & Products. โฆSee details»
Science & Products-Bioheng Therapeutics
Bioheng Therapeutics Science & Products Bioheng Therapeutics is a clinical stage company focused on allogeneic / off-the-shelf CAR-T. About. About Bioheng. History. Science & โฆSee details»
Bioheng - Funding, Financials, Valuation & Investors - Crunchbase
Bioheng is a high-tech R&D innovation company. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. Resources. Log In. Organization. ... How โฆSee details»
Bioheng Company Profile - Office Locations, Competitors ... - Craft
Bioheng (also known as Nanjing Beiheng Biotech, ๅๆ็็ฉ) is a biopharmaceutical company that focuses on immunotherapy and gene therapy for treating cancer. It also provides a range of โฆSee details»
Bioheng Biotech Raised $80 million in Series B Financing to โฆ
NANJING, China, March 24, 2021 /PRNewswire/ -- Bioheng Biotech Co., Ltd, a clinical-stage biotechnology company dedicated on developing novel cellular immunotherapy for cancer, โฆSee details»
Bioheng Raised $80 Million in Series B Financing to Advance โฆ
NANJING, China, March 24, 2021 /PRNewswire/ -- Bioheng Biotech Co., Ltd, a clinical-stage biotechnology company dedicated on developing novel cellular immunotherapy for cancer, โฆSee details»
Bioheng Biotech received Orphan Drug Designation from the U.S.
Jun 20, 2021 Bioheng is a clinical-stage biotech company focused on developing novel cellular immunotherapy. The main development pipelines include allogeneic CAR T, which is used for โฆSee details»
Bioheng Announced Oral Presentation of Its Preliminary Results of ...
Nov 10, 2020 Bioheng is a leading clinical-stage biotech company focusing on the development of novel allogeneic cellular immunotherapy for immediate treatment of patients with โฆSee details»
Bioheng Received Orphan Drug Designation (ODD) from the U.S.
Bioheng's CD7 UCAR-T and Allogeneic HSCT Sequential Therapy Study Published in the New England Journal of Medicine On April 25, 2024, The New England Journal of Medicine โฆSee details»
Bioheng Announced Oral Presentation of Its Preliminary Results of ...
NANJING, China, Nov. 10, 2020 -- Bioheng Biotech Co., Ltd, a clinical-stage biotech company focused on developing novel cellular immunotherapy to treat cancer, today announced an oral โฆSee details»
News-Bioheng Therapeutics
Bioheng's CD7 UCAR-T and Allogeneic HSCT Sequential Therapy Study Published in the New England Journal of Medicine On April 25, 2024, The New England Journal of Medicine โฆSee details»